A Phase Single-arm, Open-label study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
A new study for patients with Hodgkin's Lymphoma using study drug combination (brentuximab & bendamustine)
Sponsor: Columbia University
Enrolling: Male and Female Patients
Study Length: 11 Months
IRB Number: AAAK8753
Contact: Ahmed Sawas: 212 326 5720 / as4386@columbia.edu
Additional Study Information: The purpose of this study is to gather information about the effectiveness and safety of as drug called brentuximab vedotin when given in combination with another drug called bendamustine for Hodgkin Lymphoma. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission. Participants will receive brentuximab vedotin on Day 1 of each 21-day cycle for up to 16 cycles of treatment (for up to 336 days). Paticipants will receive bendamustine on Days 1 and 2 of study treatments. PET and CT scans as well as a physical exam and blood draw will be performed at initial screening visit.
This study is closed
Investigator
Ahmed Sawas, MD
Do You Qualify?
Have you received prior salvage therapy, including radiotherapy? Yes No
Are you currently receiving chemotherapy, radiotherapy, biologics or any other immunotherapy treatment? Yes No
Are you currently using any investigational drugs for your illness? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Ahmed Sawas
as4386@columbia.edu
212 326 5720
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE